WO2013058681A3 - Substituted phenoxyacetic acids and esters and amides thereof, comprising a 2,6-dioxo-2,3,6,7-tetrahydro-1н-purine-8-yl fragment and constituting а2a adenosine receptor antagonists, and the use thereof - Google Patents
Substituted phenoxyacetic acids and esters and amides thereof, comprising a 2,6-dioxo-2,3,6,7-tetrahydro-1н-purine-8-yl fragment and constituting а2a adenosine receptor antagonists, and the use thereof Download PDFInfo
- Publication number
- WO2013058681A3 WO2013058681A3 PCT/RU2012/000830 RU2012000830W WO2013058681A3 WO 2013058681 A3 WO2013058681 A3 WO 2013058681A3 RU 2012000830 W RU2012000830 W RU 2012000830W WO 2013058681 A3 WO2013058681 A3 WO 2013058681A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- optionally substituted
- alkyl
- hydrogen
- membered
- dioxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to novel compounds of general formula 1, namely substituted phenoxyacetic acids and esters and amides thereof, which comprise a 2,6-dioxo-2,3,6,7-tetrahydro-1H-purine-8-yl fragment and exhibit antagonist activity against A2A adenosine receptors, and to the use thereof as a therapeutic principle and agent (adjuvant) for pharmaceutical compositions and drugs, as well as to methods for treating diseases of the central nervous system, oncological diseases and viral and bacterial diseases, where R1, R2 and R3, not necessarily simultaneously, are hydrogen, C1-C5 alkyl, C3-C5 alkenyl or C3-C5 alkynyl; R4 is hydrogen, a halogen atom, a hydroxyl, C1-С3 alkyl, C1-С3 alkyloxy; R5 is hydrogen, C1-C3 alkyl, the group -C(O)R6; and R6 is a hydroxyl, C1-С5 alkyloxy, С3-С5 alkenyloxy, С3-С5 alkynyloxy, an optionally substituted amino group where the substitutes, not necessarily identical, are selected from hydrogen, C1-C5 alkyl optionally substituted with a mono- or dialkylamino group or an alkoxy group or a 5-6 membered saturated heterocyclyl comprising 1-2 heteroatoms selected from nitrogen and oxygen; pyridyl or phenyl optionally substituted with 1-3 methoxy groups; or an optionally substituted 6 membered saturated heterocyclyl optionally annulated with a 5 membered unsaturated heterocyclyl and comprising 2 nitrogen atoms, where the substitutes are selected from С1-С5 alkyl optionally substituted with a 5 membered heteroaryl comprising 1-3 heteroatoms selected from nitrogen and oxygen; or a 6 membered optionally saturated heterocyclyl comprising 1-2 nitrogen atoms optionally substituted with C1-C5 alkyl, oxo, optionally substituted with phenyl; and the broken line with an adjacent unbroken line represents a single, double or triple bond.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2011141962/04A RU2477726C1 (en) | 2011-10-18 | 2011-10-18 | Substituted phenoxyacetic acids, their esters and amides containing 2,6-dioxo-2,3,6,7-tetrahydro-1h-pyrin-8-yl fragments - a2a adenosine receptor antagonists and use thereof |
| RU2011141962 | 2011-10-18 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2013058681A2 WO2013058681A2 (en) | 2013-04-25 |
| WO2013058681A3 true WO2013058681A3 (en) | 2013-06-20 |
Family
ID=48141584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/RU2012/000830 Ceased WO2013058681A2 (en) | 2011-10-18 | 2012-10-12 | Substituted phenoxyacetic acids and esters and amides thereof, comprising a 2,6-dioxo-2,3,6,7-tetrahydro-1н-purine-8-yl fragment and constituting а2a adenosine receptor antagonists, and the use thereof |
Country Status (2)
| Country | Link |
|---|---|
| RU (1) | RU2477726C1 (en) |
| WO (1) | WO2013058681A2 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020125779A1 (en) * | 2018-12-21 | 2020-06-25 | Sunshine Lake Pharma Co., Ltd. | 8-substituted styryl xanthine derivatives and uses thereof |
| CA3126735A1 (en) | 2019-01-11 | 2020-07-16 | Omeros Corporation | Methods and compositions for treating cancer |
| WO2020216152A1 (en) * | 2019-04-24 | 2020-10-29 | Dongguan Hec New Drug R&D Co., Ltd. | 8-substituted aryl vinyl xanthine derivatives and uses thereof |
| WO2021093701A1 (en) * | 2019-11-11 | 2021-05-20 | Sunshine Lake Pharma Co., Ltd. | 8-substituted styryl xanthine derivatives and uses thereof |
| CN111018856B (en) * | 2019-12-12 | 2021-10-01 | 广东东阳光药业有限公司 | 8-Substituted styryl xanthine derivatives and uses thereof |
| CN111072663B (en) * | 2019-12-12 | 2021-10-01 | 广东东阳光药业有限公司 | 8-Substituted styryl xanthine derivatives and uses thereof |
| EP4118083A4 (en) * | 2020-03-10 | 2024-07-03 | Marvel Biotechnology | Purine compounds for treating disorders |
| WO2022174351A1 (en) * | 2021-02-19 | 2022-08-25 | Marvel Biotechnology | Purine compounds for treating disorders |
| US20250353849A1 (en) * | 2021-12-03 | 2025-11-20 | Marvel Biotechnology | Purine compounds for treating disorders |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0559893A1 (en) * | 1990-10-18 | 1993-09-15 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine derivative |
| EP0590919A1 (en) * | 1992-09-28 | 1994-04-06 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agents for parkinson's disease |
| EP0628311A1 (en) * | 1992-07-08 | 1994-12-14 | Kyowa Hakko Kogyo Co., Ltd. | Antidepressant |
| US5484920A (en) * | 1992-04-08 | 1996-01-16 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for Parkinson's disease |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200701484B (en) * | 2004-08-03 | 2008-07-30 | Biorexis Pharmaceutical Corp | Combination therapy using transferrin fusion proteins comprising GLP-1 |
| EP1838298A4 (en) * | 2004-12-17 | 2009-03-04 | Univ Pennsylvania | STILBENE DERIVATIVES AND THEIR USE FOR FIXING AND IMAGING AMYLOID PLATES |
| CN102137836B (en) * | 2008-07-28 | 2015-08-26 | 赛丹思科大学 | Compounds for the Treatment of Metabolic Diseases |
-
2011
- 2011-10-18 RU RU2011141962/04A patent/RU2477726C1/en active
-
2012
- 2012-10-12 WO PCT/RU2012/000830 patent/WO2013058681A2/en not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0559893A1 (en) * | 1990-10-18 | 1993-09-15 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine derivative |
| US5484920A (en) * | 1992-04-08 | 1996-01-16 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for Parkinson's disease |
| EP0628311A1 (en) * | 1992-07-08 | 1994-12-14 | Kyowa Hakko Kogyo Co., Ltd. | Antidepressant |
| EP0590919A1 (en) * | 1992-09-28 | 1994-04-06 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agents for parkinson's disease |
Non-Patent Citations (2)
| Title |
|---|
| DATABASE PUBMED accession no. 4663020 * |
| KASE H. ET AL.: "Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease", NEUROLOGY, vol. 61, no. 11 SUP, 2003, pages 97 - 100 * |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2477726C1 (en) | 2013-03-20 |
| WO2013058681A2 (en) | 2013-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2013058681A3 (en) | Substituted phenoxyacetic acids and esters and amides thereof, comprising a 2,6-dioxo-2,3,6,7-tetrahydro-1н-purine-8-yl fragment and constituting а2a adenosine receptor antagonists, and the use thereof | |
| EA201591204A3 (en) | NEW CHIRAL N-ACYL-5,6,7, (8-SUBSTITUTED) -TETRAHYDRO- [1,2,4] TRIAZOLO [4,3-A] PIRASINS AS SELECTIVE ANTAGONISTS OF NK-3 RECEPTOR, PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL COMPOSITION NK-3, PHARMACEUTICAL COMPOSITION ANTAGONISTS, PHARMACEUTICAL COMPOSITION NK-3 NON-MEDIATED DISORDERS NK-3 RECEPTORS AND THEIR CHIRAL SYNTHESIS | |
| SA518391518B1 (en) | N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases | |
| NO20091741L (en) | Pyrazoline Compounds as Mineral Corticoid Receptor Antagonists | |
| NO20064065L (en) | Diaminopyrimidines such as P2X3 and P2X2 / 3 antagonists | |
| AR040351A1 (en) | DERIVATIVES OF QUINUCLIDINE-AMIDA, PHARMACEUTICAL COMPOSITION, COMPOSITE PREPARATION PROCEDURE AND ITS USE TO MANUFACTURE OF MEDICINES | |
| NO20071660L (en) | Novel pyridinone derivatives and their use as positive allosteric modulators of MGLUR2 receptors | |
| DE602008005771D1 (en) | DISUBSTITUTED ALKYL-8-AZABICYCLOÄ3.2.1ÜOKTAN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | |
| NO20072371L (en) | Kinuclidine derivatives and their use as muscarinic M3 receptor antagonists | |
| MY145633A (en) | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | |
| NZ603643A (en) | Purinone derivative | |
| PH12012501800A1 (en) | 2,3 dihydro- 1h - inden- 1 - yl -2,7 -diazaspirol [ 3.5 ] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor | |
| MX390264B (en) | D2 ANTAGONISTS, SYNTHESIS METHODS AND METHODS OF USE. | |
| WO2007084914A3 (en) | Phenoxy-substituted pyrimidines as adenosine receptor antagonists | |
| NO20076060L (en) | Piperidin-4-yl amide derivatives and their use as SST receptor subtype 5 antagonists | |
| NO20092689L (en) | Quinuclidinol derivatives as muscarinic receptor antagonists | |
| RU2014121205A (en) | ASOLES DERIVATIVES | |
| MX2010002171A (en) | 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists. | |
| MX349156B (en) | Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a serotonin receptor. | |
| PH12014500775A1 (en) | Ethynyl derivatives as mglur5 allosteric modulators | |
| EA201290582A1 (en) | LIGANDS OF NEURAL NICOTIN ACETYL CHOLINE RECEPTOR αβ | |
| EA201270421A1 (en) | 1,2-DIHYDRO-2-OXOHINOLINE COMPOUNDS AS LIGANDS OF 5-NT RECEPTOR | |
| MX2013006768A (en) | Glucagon receptor modulators. | |
| EA200870591A1 (en) | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR APPLICATION AS THE NICOTINE RECEPTOR OF ACETYLCHOLINE AS LIGANDS | |
| AR068111A1 (en) | COMPOSITE PIRAZINA AND PIPERIDIN REPLACED PIPERAZINIL, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE A MEDICINAL PRODUCT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12842503 Country of ref document: EP Kind code of ref document: A2 |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 12842503 Country of ref document: EP Kind code of ref document: A2 |